Moreover, the versatility of the gene delivery platform (simple intravenous infusions) enabled the first clinical demonstrations of localized (tumor-targeted), i.e., personalized cancer vaccinations in situ—using granulocyte macrophage colony stimulating factor (GMCSF) as a first immune-stimulating payload (pulsed, following DeltaRex-G tumor debulking)—where again, significant improvements in the survival of end-stage patients were demonstrated (Gordon et al., 2008; Ignacio et al., 2010). Here, CSF2 is linked to cancer.